Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
Date:8/8/2012

EAST BRUNSWICK, N.J., Aug. 8, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six months ended June 30, 2012, which reflects the Company's continuing commercialization of KRYSTEXXA® (pegloticase) in the U.S.

Savient ended the quarter with approximately $142.2 million in cash and short-term investments, a net increase of $11.2 million for the quarter.  The increase in cash and short-term investments was primarily driven by the Company entering into definitive financing and restructuring agreements with certain of its 2018 convertible note-holders during the quarter, which raised approximately $43.1 million in net cash proceeds.

Net sales for KRYSTEXXA were $4.0 million for the second quarter of 2012, a 30% increase over the first quarter of 2012.  For the second quarter of 2012, the Company had a net loss of $16.4 million, or $0.23 per share, on total revenues of $4.6 million, compared with a net loss of $30.2 million, or $0.43 per share, on total revenues of $2.0 million for the same period in 2011.  The net loss for the first six months of 2012 was $50.6 million, or $0.72 per share, on total revenues of $8.2 million, compared with a net loss of $43.8 million, or $0.63 per share, on total revenues of $3.3 million for the same period in 2011. The net loss for the three and six-month periods ended June 30, 2012 includes a $21.8 million, or $0.31 per share, gain on the extinguishment of debt.

"We are confident in our plan, which builds upon the foundation we have established and the long term opportunity for KRYSTEXXA," said Louis Ferrari, Chief Executive Officer and President.  "To achieve that goal, we have implemented our reorganization plan and have put cost control initiatives in place that we believe will support future growth opportunities.  We
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
2. UCF nanoparticle discovery opens door for pharmaceuticals
3. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
4. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
5. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
7. Global Biopharmaceuticals Market 2011-2015
8. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
9. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
10. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
11. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Comprehensive tutorials ... use these invaluable resources. , ... Seattle, WA (PRWEB) July 16, 2009 -- OpenHelix today announced the availability of new ... The dbGaP resource is a database of genotypes and phenotypes with extensive ...
... , PHILADELPHIA and LONDON, July 15 ... leading provider of biopharmaceutical institutional research. Thomson Reuters will incorporate Sagient,s assessments, ... Forecast Module of Thomson Pharma(R) Partnering ... Forecast Module , in beta testing now ...
... , BETHESDA, Md., July 15 The American Medical ... comments to the Office of the National Coordinator (ONC) and the ... The HIT Policy Committee and its Certification/Adoption Workgroup is meeting and ... , , Dr. Ted Shortliffe, ...
Cached Biology Technology:New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 2New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 3Thomson Reuters Partners With Sagient Research 2American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification 2
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
(Date:10/16/2014)... Although monocultures can be cultivated efficiently, they are ... water caused by monoculture cultivation is becoming increasingly ... principal crop form and are regarded as the ... production – quite wrongfully, finds Bernhard Schmid, an ... advocates a novel form of agriculture and forestry. ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... R. Rodney Howell, MD, FACMG, is the recipient of ... Achievement Award. Dr. Howell is Professor of Pediatrics and ... University of Miami. Dr. Howell, president of the American ... commitment and work in the field of pediatrics and genetic ...
... A new study has estimated that over 260,000 cats and dogs ... full year since the onset of the UK recession. ... of cats and dogs, currently being cared for by UK welfare ... capacity and the number entering these organisations during a 12-month period. ...
... On March 29, 2012, the National Science Foundation ... Coalition for National Science Funding and hosted by the ... Holt (NJ-12) and Judy Biggert (IL-13) and special guests ... "For 60 years, NSF has played a central ...
Cached Biology News:Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 3Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 4Are we really a nation of animal lovers? 2Science means innovation 2Science means innovation 3
Request Info...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: